CSIMarket
 
Orasure Technologies Inc  (NASDAQ: OSUR)
Other Ticker:  
 
 
Price: $3.0300 $-0.01 -0.329%
Day's High: $3.13 Week Perf: -0.98 %
Day's Low: $ 3.01 30 Day Perf: 4.48 %
Volume (M): 482 52 Wk High: $ 4.92
Volume (M$): $ 1,461 52 Wk Avg: $3.70
Open: $3.06 52 Wk Low: $2.36



 Market Capitalization (Millions $) 227
 Shares Outstanding (Millions) 75
 Employees 501
 Revenues (TTM) (Millions $) 161
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 3

Orasure Technologies Inc
Orasure Technologies Inc. is a public health diagnostic company that specializes in the development, manufacture, and distribution of oral fluid collection devices, diagnostic kits, and platform technologies. The company, which is headquartered in Bethlehem, Pennsylvania, was founded in 2000, and it primarily focuses on developing innovative medical solutions for HIV, hepatitis C, and other infectious diseases.

Orasure Technologies has developed a range of products that are marketed in more than 100 countries worldwide. Its flagship product is the OraQuick HIV, which is the first FDA-approved and CLIA waived rapid oral fluid test for HIV-1 and HIV-2. OraQuick is very easy to use, and it provides accurate results within 20 minutes, making it an important tool for public health screening programs.

In addition to OraQuick, Orasure Technologies has developed a portfolio of other health diagnostic products. These include OraSure, an oral specimen collection device used for testing hepatitis C; Intercept, a collection device used for oral fluid drug screening; and GenoSure PRIME, a genetic sequencing test used for HIV viral load monitoring.

One of the significant achievements of Orasure Technologies is its collaboration with the Centers for Disease Control and Prevention (CDC) to develop the first at-home HIV testing kit named "OraQuick In-Home HIV Test." The kit is marketed directly to the general public and provides an accessible home testing option, helping people control their HIV status and make informed decisions about their health.

Orasure Technologies has been recognized for its innovative technologies and outstanding business practices. It has been awarded numerous patents for its products and has been listed among the top 25 innovative companies by the Technology Fast 500 list in 2015.

In summary, Orasure Technologies Inc is a global industry leader in the public health diagnostic field, with products that are making a tremendous impact on combating the spread of infectious diseases such as HIV and hepatitis. The company has demonstrated a commitment to innovation and its corporate values of reliability, innovation, and excellence in serving its customers.


   Company Address: 220 East First Street Bethlehem 18015 PA
   Company Phone Number: 882-1820   Stock Exchange / Ticker: NASDAQ OSUR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BDX     
BSX     
ESTA     
IRIX     
VERO     
ZYXI     
• View Complete Report
   



Shares

OraSure Technologies Authorizes $40 Million Stock Buyback as Part of Strategic Growth and Innovation Efforts,

Published Mon, Mar 24 2025 11:30 AM UTC

OraSure Technologies Announces $40 Million Stock Repurchase Plan Amidst Strategic AdvancementsIn a significant financial move, OraSure Technologies, Inc. a prominent player in the field of point-of-need and home diagnostic tests, announced on March 24, 2025, that its Board of Directors has authorized a stock repurchase program valued at up to $40 million. The initiative is s...

Product Service News

Rapid Responses OraSure Technologies Advances Marburg Virus Testing with Federal Backing,

Published Mon, Dec 2 2024 12:05 PM UTC

On December 2, 2024, OraSure Technologies, Inc. (NASDAQ: OSUR), a pioneering entity in point-of-care and home diagnostic tests, announced a significant advancement in infectious disease detection through its recent award from the Rapid Response Partnership Vehicle (RRPV). This pivotal funding, provided by the Biomedical Advanced Research and Development Authority (BARDA) a c...

Management Announcement

OraSure Technologies Leads the Fight Against HIV: Supports National HIV Testing Day to Make a Lasting Impact

Published Thu, Jun 27 2024 11:05 AM UTC

OraSure Technologies Support for National HIV Testing Day
BETHLEHEM, Pa., June 27, 2024 - OraSure Technologies, Inc. (NASDAQ: OSUR), a renowned provider of point-of-care and home diagnostic tests, along with sample management solutions, has proudly announced its unwavering support for HIV testing initiatives nationwide, in commemoration of National HIV Testing Day. Th...

Orasure Technologies Inc

Orasure Technologies Inc Faces Financial Setback in First Quarter of 2024

In the first quarter of 2024, Orasure Technologies Inc faced a challenging financial period, with the company slipping into a deficit of $-0.05 per share compared to $0.37 in the same quarter a year before. Additionally, Income per Share fell from $0.26 to $0.05 from the preceding quarter. The sharp drop in revenue by -65.111% to $54.07 million from $154.96 million in the comparable quarter a year before was certainly a cause for concern. Sequentially, revenue fell by -28.841% from $75.98 million.
It is important to note that the rest of the Medical Equipment & Supplies sector recorded a top-line improvement in the first quarter of 2024, indicating that the challenges faced by Orasure Technologies Inc may not be industry-wide, but rather specific to the company itself.

Management Changes

NOWDiagnostics Appoints Dr. Stephen S. Tang as Chairman of the Board, Bolstering Industry Expertise and Driving Innovation in Diagnostic Healthcare

Published Thu, Mar 21 2024 12:31 PM UTC



NOWDiagnostics, a leading developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, has recently named Dr. Stephen S. Tang as the chairman of the company s board of directors. Dr. Tang brings a wealth of experience and industry expertise to the table, having been a longstanding veteran of the medical diagnostic industry.
Prior to joining NOW...







Orasure Technologies Inc's Segments
Product and Services    98.97 % of total Revenue
Product and Services Revenues HIV    44.03 % of total Revenue
Product and Services Revenues Sample Management Solutions    31.09 % of total Revenue
Product and Services Revenues HCV    14.79 % of total Revenue
Product and Services Revenues Risk assessment testing    4.85 % of total Revenue
Product and Services Revenues Other product and services revenues    2.64 % of total Revenue
Product and Services Revenues COVID-19    1.57 % of total Revenue
Other    102.16 % of total Revenue
Other Non-product and services revenues    3.19 % of total Revenue
United States    69.41 % of total Revenue
Africa    24.54 % of total Revenue
Europe    5.59 % of total Revenue
Other regions    2.63 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com